VALFIX Medical Overview
VALFIX has created a revolutionary mitral valve repair system. The technology was designed to fully convert open heart valve surgery into a transcatheter procedure. Severe functional mitral regurgitation (FMR) affects millions of patients. Due to high surgical risks, only a small percentage of patients undergo open-heart valve surgery. Nearly half of the remaining patients, who are treated with medication only, will die within two years. VALFIX system offers a solution to the millions of patients currently without viable treatment. VALFIX’s innovative and game-changing system allows cardiologists to perform transcatheter mitral valve repair procedures to alleviate heart failure symptoms, improve quality of life, and save lives.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
VALFIX Medical Inc. Announces the Issuance of a New U.S. Patent for Its Mitral Valve Repair Technology
VALFIX Medical Inc. has announced the issuance of a new patent by its Israeli subsidiary, VALFIX Medical Ltd. The patent, titled Anchors and locks for percutaneous valve implants, outlines innovative locking mechanisms that enhance the stability and precision of valve implants. This development is seen as a significant step forward in the companys technology, providing a unique approach to valve repair that closely replicates surgical annuloplasty. The patent is expected to add considerable value to VALFIX Medicals stakeholders and solidify its position in the market. The companys CEO, Eli Bar, expressed excitement about the patent, emphasizing its role in protecting and confirming the core technology of VALFIX Medical.
growth-positive
VALFIX Medical Inc. Secures Fifth Consecutive Grant from the Israel Innovation Authority - valfix medical
VALFIX Medical, a leader in transcatheter mitral valve repair, has secured its fifth consecutive grant from the Israel Innovation Authority (IIA). This grant underscores the ongoing partnership between VALFIX and the IIA, highlighting the companys commitment to technological advancement. CEO Eli Bar emphasized the significance of this support, which, along with backing from investors, will help the company progress towards its first-in-human study within the next year. Since 2017, VALFIX has received over 3 million USD in grants from the IIA, reflecting the authoritys confidence in the companys achievements and future plans.
InvestmentPartners
growth-positive
VALFIX Medical Inc. Appoints Former Abbott Ventures DVP, Evan Norton as New Independent Board Member - valfix medical
VALFIX Medical Inc. has appointed Evan Norton, a former Abbott Venture Divisional Vice President, as an independent board member. This strategic move is expected to bolster the companys leadership as it continues to grow and advance its MedTech innovations. Evan Norton brings a wealth of experience from his tenure at Abbott, where he managed minority equity investments and acquisitions. His expertise is anticipated to be a valuable asset for VALFIX as it pursues its goals. The appointment reflects confidence in VALFIXs leadership and its potential for continued success in the medical technology sector.
Management Changes
growth-positive
VALFIX Medical Inc. Secures Investment from California Based Angel Group, Life Science Angels - valfix medical
VALFIX Medical Inc. has secured an investment from Life Science Angels (LSA), marking the conclusion of its third investment round. This funding will support the development of VALFIXs transcatheter solution for treating severe Mitral Regurgitation (MR), a condition affecting heart failure patients. The investment process was led by Dr. Gary Gershony, who facilitated the connection between VALFIX and the investing group, which includes members from the Band of Angels and other private investors. The funds will be used to advance VALFIXs innovative multi-wire technology towards clinical testing, offering a promising alternative to open-heart surgery.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $8.76M |
| Last funding | $3.6M |
| Stage | Seed |
| Rounds | 8 |
| Investors | 2 |
Team Members
3
Employees: 1-10
Web & Social Links
| Website | www.valfixmed.com/ |
Locations
Menorat HaMa'or St 3, Tel Aviv-Yafo, Israel
850 New Burton Rd, Dover, DE 19904, USA
Photos & Videos
5 item(s)
